NASHVILLE, TN – May 29, 2012 – The American Society of Clinical Oncology (ASCO) has selected 60 abstracts authored by Sarah Cannon Research Institute (SCRI) for presentation at the 2012 ASCO Annual Meeting, the premier educational and scientific oncology conference, which takes place June 1-5 in Chicago.
The 60 presentations include nine abstracts in disease-specific oral sessions, as well as 14 poster discussions; 28 general posters, and 9 Trials in Progress posters. A complete schedule of the presentations can be found on sarahcannonresearch.com. In addition, five abstracts were accepted for publication.
The studies selected include those focusing on the efficacy of new treatments for breast, lung, and gastrointestinal cancers, as well as blood cancers and carcinomas of unknown primary. Several trials highlight the success of exploratory molecular assays in advancing personalized medicine. The collaborative effort of physician researchers across the SCRI community-based network in the United States and United Kingdom enabled the completion of this innovative clinical research.
“ASCO’s selection of 60 abstracts authored by our investigators demonstrates that we are fulfilling our mission of advancing therapies for patients,” SCRI CEO Dee Anna Smith said. “The record number of acceptances for SCRI in 2012 is a tribute to the efforts of our entire team and especially to the cancer patients who participated in these important clinical trials.”
Three studies were chosen for the Best of ASCO program, which condenses highlights from ASCO’s Annual Meeting into a two-day program and reflects research that is considered particularly relevant to the practice of oncology.
Johanna C. Bendell, M.D., SCRI Director, GI Cancer Research Program is the first author and presenter of one of the Best of ASCO abstracts: a phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) vs. placebo plus capecitabine (CAP) in patients with refractory metastatic colorectal cancer. In addition, Dr. Bendell will deliver the lecture, “Colorectal Cancer Treatment is ready for Personalization, why is it not being used?” at an educational session.
Two of the first-in-man Phase I studies led by the SCRI Drug Development Program were chosen for oral presentations. SCRI Senior Investigator, Kent Shih, M.D., will present a phase I trial of the oral TORC1/TORC2 Inhibitor CC-223 in advanced solid and blood cancers. SCRI Drug Development Investigator Shubham Pant, M.D., Oklahoma University Medical Center, will discuss a study of the oral Notch inhibitor, LY90009, in patients with advanced cancer.
Additionally, six other abstracts were selected for presentation at a clinical science symposiums (CSS) or disease-specific oral sessions. These highlighted CSS forums incorporate the presentation of meritorious abstracts with an instructive lecture by an expert who summarizes the field and places the abstracts in context, focusing on how the findings apply to clinical practice.
The following SCRI principal investigators will also present educational sessions at the meeting:
Chief Medical Officer, Howard A. Burris III, MD will review the development of T-DM1, a promising new targeted breast cancer treatment. SCRI investigators have been closely involved with the development of this important drug beginning with the first-in-human study. Dr. Burris’ talk, “T-DM1: Hitching a Ride on a Therapeutic Antibody.” will be presented at the Antibody Drug Conjugates session.
Jeffrey Infante, M.D, SCRI Director of Drug Development, will lead two educational programs titled, “Expansion Cohorts as a Means for Activity Signal” and “Inclusion of Patients with Brain Metastases in Clinical Trials”.
Other SCRI investigators with presentations include: Hendrik-Tobias Arkenau, M.D., Ph.D., John Barton, M.D., Jesus Berdeja, M.D., Irfan Firdaus, M.D., Ian Flinn, M.D., Ph.D., Victor Gian, M.D., F. Anthony Greco, M.D., John Hainsworth, M.D., Carla Kurkjian, M.D., Kathleen Moore, M.D., Manish Patel, M.D., Mark Rubin, M.D., Michael Savona, M.D.,
Dianna Shipley, M.D., David Spigel, M.D., Dana Thompson, M.D., David Waterhouse, M.D., and Denise Yardley, M.D.,
About SCRI
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US. Please click here to earn more about our research offerings.